Madrigal Pharma (MDGL) Reports Prelim Q4
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Madrigal Pharmaceuticals (MDGL) PT Raised to $392 at Evercore ISI
January 13, 2025 11:04 AM ESTEvercore ISI analyst Liisa Bayko raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $392.00 (from $360.00) while maintaining a Outperform rating.
The analyst comments "MDGL had another solid quarter, preannouncing 4Q Rezdiffra revenue of $100M-$103M, giving a strong beat to consensus and our... More



